The DKA that wasn't: A case of euglycemic diabetic ketoacidosis due to empagliflozin

Oxford Medical Case Reports

Volumn 2016, Issue 7, 2016, Pages 144-146

  Candelario, Nellowe ^a   Wykretowicz, Jedrzej ^a  

^a Einstein Healthcare Network   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN;

ABDOMINAL PAIN; ADULT; ANION GAP; ARTERIAL GAS; ARTICLE; BICARBONATE BLOOD LEVEL; CASE REPORT; CHOLECYSTECTOMY; DIABETIC KETOACIDOSIS; EMERGENCY WARD; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HOSPITAL ADMISSION; HUMAN; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; LAPAROSCOPIC CHOLECYSTECTOMY; LEUKOCYTE COUNT; MIDDLE AGED; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; ULTRASOUND; URINALYSIS;

EID: 85007294530     PISSN: None     EISSN: 20538855     Source Type: Journal    
DOI: 10.1093/omcr/omw061     Document Type: Article

References (10)

1. Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin 2009;25:671-81. doi:10.1185/03007990802710422. Review. PubMed PMID: 19232040.
2. Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis. Diabetes Obes Metab 2016; doi:10.1111/dom.12670. [Epub ahead of print] PubMed PMID: 27059700.
3. U.S. Food and Drug Administration Drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections [Internet]. 15 May 2015. Avaialbe from http://www.fda.gov/drugs/drugsafety/ucm475463.html (9 May 2016, date last accessed).
4. Modi A, Agrawal A, Morgan F. Euglycemic diabetic ketoacidosis. Curr Diabetes Rev 2016; [Epub ahead of print] PubMed PMID: 27097605.
5. Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig 2016;7:135-8. doi:10.1111/jdi.12401. Epub 2015 Sep 6. PubMed PMID: 27042263; PubMed Central PMCID: PMC4773669.
6. Brockman RP. Roles for insulin and glucagon in the development of ruminant ketosis-a review. Can Vet J 1979;20:121-6. Review. PubMed PMID: 385136; PubMed Central PMCID: PMC1789550.
7. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015;38:1638-42. doi:10.2337/dc15-1380. PubMed PMID: 26294774.
8. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015;38:1687-93. doi:10.2337/dc15-0843. Epub 2015 Jun 15. PubMed PMID: 26078479; PubMed Central PMCID: PMC4542270.
9. Kamalakannan D, Baskar V, Barton DM, Abdu TA. Diabetic ketoacidosis in pregnancy. Postgrad Med J 2003;79:454-7. Review. PubMed PMID: 12954957; PubMed Central PMCID: PMC1742779.
10. Gelaye A, Haidar A, Kassab C, Kazmi S, Sinha P. Severe ketoacidosis associated with canagliflozin (Invokana): a safety concern. Case Rep Crit Care 2016;2016:1656182. doi:10. 1155/2016/1656182. Epub 2016 Mar 21. PubMed PMID: 27088018; PubMed Central PMCID: PMC4819091.